Femasys Engages in a Fireside Chat at Major Investment Conference
Femasys, Inc. (Nasdaq: FEMY), a frontrunner in biomedical solutions for women's health, is gearing up for a key appearance at the H.C. Wainwright 26th Annual Global Investment Conference. During this event, Kathy Lee-Sepsick, the company's Founder, President, and CEO, will participate in a fireside chat moderated by Life Sciences Analyst, Emily Bodnar. This conference provides an excellent opportunity for investors and innovators to connect and explore the latest advancements in healthcare.
Event Details and Access
Final preparations are underway for the conference, which will take place from September 9 to September 11. Kathy Lee-Sepsick is scheduled to speak on September 9, 2024. Attendees can access a pre-recorded segment featuring Femasys' newest products starting at 7:00 AM ET. Following the live event, the presentation will be available on-demand for up to 90 days in the investor relations section of Femasys's website.
Opportunity for One-on-One Meetings
Kathy Lee-Sepsick and Dov Elefant, the Chief Financial Officer, will be available for direct engagement with attendees through one-on-one meetings. Interested individuals are encouraged to request a meeting to discuss Femasys' innovative solutions and investment opportunities during the conference.
About Femasys and Its Innovations
Femasys is dedicated to enhancing women's healthcare through a range of innovative products. The company has developed several important therapeutic and diagnostic solutions that address vital needs in reproductive health. One of its standout products is FemaSeed, an FDA-cleared intratubal insemination solution that increases the likelihood of conception by delivering sperm directly to the fertilization site. Additionally, FemBloc, a non-surgical and permanent birth control method, is in the late stages of clinical development, aiming to offer women safer and more affordable options compared to traditional surgical methods.
Regulatory Approvals and Market Readiness
Femasys has received regulatory approvals for various products across multiple regions, including the U.S., Canada, and Europe. The company's manufacturing capabilities ensure that diagnostic tools like FemVue, FemVue Mini, and FemCerv are ready for market and accessible to women who need them. Each product is designed to work together, providing comprehensive solutions to address women's healthcare challenges.
Conclusion and Future Directions
As Femasys continues to innovate and broaden its product offerings, its participation in major events like the H.C. Wainwright conference reinforces the company's position as an industry leader committed to improving women's health. With a strong portfolio and ongoing clinical developments, Femasys is well-equipped to meet the increasing needs of women worldwide.
Frequently Asked Questions
What is the H.C. Wainwright conference?
The H.C. Wainwright conference is an annual gathering where companies showcase their innovations and engage with investors in the life sciences sector.
Who is presenting at the Femasys fireside chat?
Kathy Lee-Sepsick, the Founder and CEO of Femasys, will be the presenter at the fireside chat.
What innovative products does Femasys offer?
Femasys provides solutions like FemaSeed for intratubal insemination and FemBloc for non-surgical permanent birth control.
How can I access the webcast of the presentation?
The webcast will be available on the Femasys investor relations website and can be accessed on-demand.
What opportunities are available for investors at the conference?
Investors can request one-on-one meetings with Femasys executives to discuss potential investments and product innovations.
